Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORQUEST FE vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
NORQUEST FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Norethindrone induces progestational changes in the endometrium, increasing cervical mucus viscosity, and also inhibits ovulation.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Prevention of pregnancy
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
One tablet orally once daily, each tablet containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol (21 active tablets) followed by 7 ferrous fumarate tablets.
400 mg orally once daily with food.
Terminal half-life: 6-8 hours. Clinical context: Supports once-daily dosing with sustained therapeutic effect.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Ethinyl estradiol is metabolized via CYP3A4, with phase II conjugation (glucuronidation and sulfation). Norethindrone is metabolized via reduction and conjugation, primarily as sulfate and glucuronide conjugates.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Renal: 80% (50% unchanged, 30% as metabolites); Fecal: 19%; Biliary: <1%
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
97% bound to albumin and α1-acid glycoprotein.
98% bound to albumin
Vd: 3.5 L/kg (~245 L for 70 kg adult). Indicates extensive tissue distribution.
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral: 92% (range 88-96%)
Oral: 85-90%; IM: 95-100%
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in severe renal impairment (GFR <30 m L/min) due to lack of data.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in patients with hepatic impairment (Child-Pugh Class B or C). No specific dose adjustment for mild impairment; use with caution.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Safety and efficacy not established in postmenarchal patients; dosing follows adult regimen if indicated.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not indicated for use in postmenopausal women; no specific dose adjustment recommended due to lack of data.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. Women over 35 years old who smoke should not use this product.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Increased risk of thromboembolic disorders, cardiovascular disease (especially in smokers over 35), hepatic neoplasia, gallbladder disease, hypertension, and glucose intolerance. Use with caution in women with risk factors for these conditions.
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
History of thrombophlebitis or thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected pregnancy, carcinoma of the breast, estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, jaundice with prior OCs, liver adenoma or carcinoma, hepatic impairment, and hypersensitivity to any component.
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
Avoid calcium-rich foods (milk, yogurt, cheese) within 2 hours of dose. Vitamin C (citrus fruits, tomatoes) enhances iron absorption. Coffee, tea, and red wine reduce iron absorption; avoid within 1 hour of dosing.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: estrogen exposure associated with congenital anomalies including cardiovascular and neural tube defects. Second/third trimesters: linked to vaginal adenosis and cervical dysplasia in female offspring, potential for genitourinary abnormalities. Use of iron and calcium components generally safe, but hormonal components (estrogen/norethindrone) pose teratogenic risk.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Not recommended during breastfeeding. Estrogen and progestin may reduce milk production and quality. Small amounts of steroids and iron are excreted in breast milk; M/P ratio not established for combined hormonal contraceptives. No specific data for NORQUEST FE; avoid use.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
Contraindicated in pregnancy; no dose adjustments recommended as drug should be discontinued. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) would necessitate dose increase if used, but use is contraindicated.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
Contains norethindrone acetate and ethinyl estradiol. Use for iron deficiency anemia due to menstrual blood loss; iron absorption enhanced with vitamin C. Monitor for thromboembolic events, especially in smokers over 35. May reduce menstrual flow and improve iron stores over 3-6 months.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one tablet daily at the same time with food to reduce nausea.,Iron may cause dark stools; this is harmless.,Avoid taking with dairy, calcium supplements, or antacids within 2 hours.,Report signs of blood clots: leg pain, chest pain, shortness of breath.,Continue for full course even if bleeding improves to prevent recurrence.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORQUEST FE vs ADQUEY, answered by our medical review team.
NORQUEST FE is a Oral Contraceptive that works by NORQUEST FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Norethindrone induces progestational changes in the endometrium, increasing cervical mucus viscosity, and also inhibits ovulation.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORQUEST FE and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORQUEST FE is: One tablet orally once daily, each tablet containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol (21 active tablets) followed by 7 ferrous fumarate tablets.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORQUEST FE and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORQUEST FE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: estrogen exposure associated with congenital anomalies including cardiovascular and n. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.